From: Lung function and microbiota diversity in cystic fibrosis
Lung disease categorya | ||||
---|---|---|---|---|
Severe | Moderate | Mild | ||
All patients | < 40% | 40–69% | ≥ 70% | |
Number of patients | 299 | 101 | 139 | 57 |
Sex (female:male) | 137:160 | 39:62 | 66:73 | 32:25:00 |
Mean age (±SD)b | 29.9 (± 10.2) | 30.0 (± 10.8) | 29.7 (± 10.1) | 30.5 (± 9.5) |
Mean %FEV1 (±SD) | 49.5 (± 22.0) | 25.5 (± 7.7) | 53.2 (± 8.4) | 82.8 (± 9.2) |
CFTR Genotypec | ||||
Homozygous F508del | 153 | 46 | 75 | 32 |
Heterozygous F508del | 105 | 38 | 47 | 20 |
Non-F508del | 39 | 17 | 17 | 5 |
Clinical status (stable:exacerbation)d | 86:211 | 43:58 | 38:101 | 5:52 |
CF related diabetes | 119 | 54 | 50 | 15 |
Pancreatic insufficiency | 250 | 91 | 111 | 48 |
Region | ||||
Europe | 161 | 58 | 73 | 30 |
USA | 136 | 43 | 66 | 27 |
CF Centre | ||||
Bedford, NH, USA | 17 | 5 | 9 | 3 |
Belfast, Northern Ireland | 27 | 12 | 13 | 2 |
Boston, MA, USA | 16 | 6 | 5 | 5 |
Burlington, VT, USA | 30 | 8 | 17 | 5 |
Dublin, Ireland | 1 | 0 | 1 | 0 |
Lebanon, NH, USA | 6 | 2 | 2 | 2 |
London, UK | 6 | 1 | 5 | 0 |
New York, NY, USAe | 5 | 2 | 1 | 0 |
Newcastle, UK | 26 | 16 | 8 | 2 |
Portland, ME, USA | 25 | 14 | 6 | 5 |
Seattle, WA, USA | 39 | 6 | 26 | 7 |
Southampton, UK | 94 | 29 | 39 | 26 |
Warsaw, Poland | 7 | 0 | 7 | 0 |
Antibioticsf | ||||
Amikacin | 12 | 6 | 6 | 0 |
Azithromycin | 64 | 34 | 22 | 8 |
Aztreonam | 59 | 24 | 27 | 8 |
Ceftazidime | 55 | 20 | 30 | 5 |
Ciprofloxacin | 17 | 3 | 12 | 2 |
Colistin | 59 | 32 | 21 | 6 |
Co-trimoxazole | 13 | 5 | 5 | 3 |
Flucloxacillin | 24 | 14 | 9 | 1 |
Fosfomycin | 10 | 5 | 5 | 0 |
Meropenem | 42 | 16 | 21 | 5 |
Tobramycin | 120 | 49 | 52 | 19 |
Other antibiotics | 113 | 39 | 58 | 14 |